Rein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Update

Rein Therapeutics Inc. (NASDAQ:RNTX) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 351,493 shares, an increase of 76.0% from the December 31st total of 199,688 shares. Based on an average daily volume of 131,187 shares, the short-interest ratio is currently 2.7 days. Currently, 1.4% of the shares of the company are short sold. Currently, 1.4% of the shares of the company are short sold. Based on an average daily volume of 131,187 shares, the short-interest ratio is currently 2.7 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on RNTX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Thursday, January 22nd. Brookline Capital Management cut Rein Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 21st. Loop Capital set a $6.00 price objective on Rein Therapeutics in a report on Monday, November 3rd. Wall Street Zen cut Rein Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 14th. Finally, Citigroup cut shares of Rein Therapeutics to a “hold” rating in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $8.00.

Rein Therapeutics Price Performance

Shares of NASDAQ RNTX opened at $1.30 on Friday. The business has a fifty day moving average price of $1.34 and a two-hundred day moving average price of $1.31. The stock has a market capitalization of $34.17 million, a PE ratio of -0.49 and a beta of 1.31. Rein Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $2.96.

Rein Therapeutics (NASDAQ:RNTX) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. On average, equities analysts expect that Rein Therapeutics will post -1.56 EPS for the current year.

Insider Buying and Selling at Rein Therapeutics

In related news, major shareholder Voss Capital, Lp bought 104,183 shares of the business’s stock in a transaction dated Friday, November 14th. The stock was bought at an average price of $1.22 per share, for a total transaction of $127,103.26. Following the purchase, the insider owned 926,441 shares in the company, valued at $1,130,258.02. This represents a 12.67% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Voss Capital LP lifted its position in shares of Rein Therapeutics by 86.0% during the 3rd quarter. Voss Capital LP now owns 2,666,532 shares of the company’s stock worth $3,053,000 after buying an additional 1,232,846 shares during the last quarter. BIOS Capital Management LP acquired a new position in shares of Rein Therapeutics during the second quarter worth $2,367,000. Vanguard Group Inc. lifted its holdings in Rein Therapeutics by 32.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock worth $1,338,000 after buying an additional 284,300 shares during the period. Prosight Management LP grew its position in shares of Rein Therapeutics by 32.7% in the 3rd quarter. Prosight Management LP now owns 567,898 shares of the company’s stock valued at $650,000 after buying an additional 139,979 shares during the last quarter. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Rein Therapeutics in the second quarter valued at about $716,000. 90.89% of the stock is owned by institutional investors.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.